News

HumanZyme(r) Announces Human Cell-Expressed Interferon gamma for Immunology and Immunotherapy Research Applications

Chicago, IL. – September 21, 2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine(r) Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma, also known as Type II interferon, protects against bacterial, viral and protozoan infections, and is produced by TH-1 or NK cells. Important research is underway on the immunomodulatory activity of IFN gamma, including stimulation of cell-based immunity and cytotoxicity. IFN gamma has been evaluated for use in a variety of clinical applications including as an anti-cancer biotherapeutic, and is FDA approved for the treatment chronic granulomatous disease (CGD) and severe, malignant osteoporosis.

According to Scott Coleridge, CEO at HumanZyme, “Recombinant human IFN-beta is the latest offering in a series of new, high-quality, HEK293-expressed cytokines that are difficult to manufacture. Using our proprietary HEK293 expression system, we are proud to be one of only a few commercial suppliers to offer tag-free recombinant human Interferon gamma expressed in human cells for research purposes. The new IFN gamma further expands our recombinant human interferon product offering to include IFN alpha 2a, IFN alpha 2b, IFN beta, and now IFN gamma.”

IFN gamma has two N-linked glycosylation sites, Asn-25 and Asn-97, on the surface of the dimer, and glycosylation is essential to its half-life in human serum and its full biological activity. Producing IFN gamma in HEK293 cells assures native processing, glycosylation and folding of the purified protein compared to bacterial and mammalian cell lines, or insect cell expression systems. HumanZyme’s HumanKine proteins are high quality, are animal-derived product free, xeno-free and carrier-free, and are available in bulk.

For more information, see our Interferon gamma product page.

Human Cell-Expressed Interferon beta for Stem Cell Research and Regenerative Medicine Applications

Chicago, IL. — June 27, 2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is a member of the type I family of interferons whose function is inhibiting viral infection, along with the regulation and activation in immune responses against bacteria, parasites and tumor cells. IFN beta is deficient in multiple sclerosis, and is currently used in injectable form as a treatment for this disease.

According to Scott Coleridge, CEO at HumanZyme, “We are proud to be the only commercial supplier of high-quality, tag-free recombinant human Interferon beta expressed in human cells for research purposes. Our proprietary HEK293 expression system allows us to express difficult proteins in a human cell line to provide the most authentic recombinant products possible. The new IFN beta further expands our animal component-free HumanKine product line, is priced competitively, is and is also available in bulk.”

Glycosylation of the Interferon beta protein by a single asparagine-linked sugar chain has been shown to be essential to its activity and stability, both in vitro and in vivo. HumanZyme’s IFN beta expressed in human cells assures native processing, glycosylation and folding of the purified protein compared to other expression systems such as bacterial, mammalian cell lines, or insect cells, preserving its biologic function and activity. HumanZyme’s HumanKine proteins are also animal-derived product free, xeno-free and carrier-free.


HumanZyme® Launches Human Cell-Expressed Wnt3A Protein for Stem Cell Research and Regenerative Medicine Applications

Chicago, IL. — December 12, 2016

HumanZyme Inc., a leading supplier of novel human proteins and growth factors expressed in human cells today announced the launch of Wnt3AHuXp, a new addition to their HumanKine® authentic recombinant human protein product line. Wnt3a is a widely used reagent for the in vitro self-renewal and differentiation of human embryonic stem cell cultures, and is an important tool for stem cell and cell therapy researchers.

According to Scott Coleridge, CEO at HumanZyme, “This is a very difficult protein to make and we are quite proud to be one of the very few companies to offer human cell-produced Wnt3A. Our R&D team worked very hard to make this possible. Wnt3A is an important addition to our high-quality HumanKine authentic recombinant human cytokines and growth factors used for stem cell expansion, differentiation and maintenance. The new Wnt3a product is priced competitively, is animal-derived product free and available in bulk,” said Scott Coleridge, CEO at HumanZyme.

Wnt3A is a highly-conserved, cysteine-rich glycosylated protein whose biological activity is dependent on correct glycosylation and acylation. Expression of Wnt3A in human cells with native processing, glycosylation and folding ensures native activity compared to other expression systems such as bacterial, mammalian cell lines, or insect cells. HumanZyme’s HumanKine proteins are also animal-free, xeno-free and carrier-free. The new Wnt3A offering expands the HumanKine product line of recombinant human proteins expressed in human cells available from HumanZyme.


HumanZyme® Launches New LIF (Leukemia Inhibitory Factor) Protein, Expanding Product Line For Stem Cell Research

Chicago, IL. — August 10, 2016

HumanZyme Inc., a leading supplier of novel human proteins and growth factors to academic and biopharmaceutical customers enabling stem cell research and regenerative therapy applications, today announced the launch of a new HumanKine® product line protein, LIFHuXp (Leukemia Inhibitory Factor). LIF is used to promote long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation when added to culture medium.
“The new LIF HumanKine product is an important addition to our recombinant human cytokines and growth factors for stem cell research. We are working hard to expand our offerings to be a complete set of recombinant proteins used for stem cell expansion, differentiation and maintenance. LIF is priced competitively, is animal-derived product free and available in bulk,” said Scott Coleridge, CEO at HumanZyme.
HumanKine recombinant human cytokines and growth factors are expressed in HEK293 cells for native human post-translational processing, including glycosylation, disulfide links, and folding, and provide optimal activity in stem cell cultures.


HumanZyme Launches New XKine™ Recombinant Protein Line For Stem Cell Research and Regenerative Medicine Applications

March 1, 2016

HumanZyme Inc., a leading supplier of novel human proteins and growth factors to academic and biopharmaceutical customers enabling stem cell research and regenerative therapy applications, launched the new XKine™ product line broadening the company’s product offering. The new XKine™ human recombinant proteins are manufactured utilizing EColi or Chinese Hamster Ovary (CHO) host cell lines, expanding the number of research applications supported by HumanZyme.

“The new XKine products are priced competitively selected carefully to support current pathway analysis, allowing our customers to purchase these products from HumanZyme, without the need to go to a 3rd party supplier as previously required, ” said Scott Coleridge, CEO at HumanZyme. The new XKine recombinant human protein line includes IL-11, IL-15, IL-34, IL35, IL5, IL8(CxXL8), LIF, Neurturin, PDGF-BB, Rantes(CCL5) sCD40 ligand, sTrail/apo2L, BDNF, CTGF, EGF and FGF-acidic etc. We will keep adding more recombinant proteins and cytokines to this growing product line.

Upcomming Summit

February 29-March 02, 2016

Join HumanZyme at the 6th World Congress on Cell & Stem Cell Research, Philadelphia, Pennsylvania, USA.

The topic for this year’s summit will be “Novel Therapies in Cell Science and Stem Cell Research”.

Upcoming Tradeshows

October 7th-9th, 2015 – Stem Cell Meeting on the Mesa, La Jolla, CA

October 15th, 2015 – University of Arizona, Tucson, AZ

October, 20th, 2015 – Children’s Hospital, Los Angeles, CA

October 29th, 2015 – University of Utah, Salt Lake City, UT

November 2nd, 2015 – University of Southern California, Los Angeles, CA

November 3rd, 2015 – University of California Irvine, Irvine, CA

November 5th, 2015 – University of Los Angeles, Los Angeles, CA

November 12, 2015 – USC Broad CIRM Center, Los Angeles, CA

December 8, 2015 – University of California Irvine, Irvine CA

HumanKine FGFbasic-TS™ (Thermostable) Now Available

November 22, 2013

HumanKine® FGFbasic-TS™ is expressed in human 293 cells. FGFbasic is a heparin-binding growth factor and critical for human embryonic stem cells to remain in an undifferentiated state during cell culture. HumanKine® FGFbasic-TS™ is engineered to enhance its thermo-stability without modification of biological function. HumanKine® FGFbasic-TS™ is a 17 kDa non-glycosylated monomer consisting of 154 amino acids.

Read More

HumanKine Pleitrophin (PTN) Now Available

June 1, 2013

Xeno-free HumanKine® Pleiotrophin is expressed in human 293 cells as a secreted unglycosylated monomer. Production in human 293 cells uses a serum-free, chemically defined media and offers authentic properties. Cytokines produced in bacteria or insect cells (sf9 or sf21) have post-translational modifications which are not human like.

Read More

HumanKine IL-7 Now Available

May 1, 2013

Xeno-free HumanKine® IL-7 is expressed in human 293 cells as a highly glycosylated protein. Under reducing conditions IL-7 migrates as three separate bands at 19 kDa, 25 kDa and 30 kDa. In comparision, IL-7 produced in an E. coli expression system have no glycosylation and migrate as a single band at 17 kDa. Production in human 293 cells uses a serum-free, chemically defined media and offers authentic glycosylation.

Read More

HumanKine IL-27 Now Available

March 19, 2013

IL-27 is a heterodimeric cytokine which exhibits a range of pro- and anti-inflammatory properties through T Cell regulation. In addition to its immune-regulatory functions, IL-27 has been reported to demonstrate anti-viral activity in HIV-1 and HCV. HumanZyme now offers tag-free, human cell expressed authentic HumanKine IL-27 with no artificial linker and human glycosylation.

Read More